SYDNEY, Australia — Apomorphine may represent a novel therapeutic agent to reduce the burden of cognitive impairment in patients with Parkinson's disease (PD). Preliminary findings from a study from ...
TORONTO, ONTARIO--(Marketwired - May 15, 2013) - Cynapsus Therapeutics Inc. (TSX VENTURE:CTH), a specialty pharmaceutical company developing the only known orally administered (sublingual) formulation ...
Please provide your email address to receive an email when new articles are posted on . Apomorphine sublingual film resulted in greater motor improvement and an increase in responders at earlier time ...
The difference in score change for movement disorder from baseline to 30 minutes post-dose between the apomorphine and placebo group was 7.6 (P=0.0002). Sunovion announced that apomorphine sublingual ...
The Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for SPN-830, an apomorphine infusion device for the continuous treatment of motor fluctuations ...
Please provide your email address to receive an email when new articles are posted on . Apomorphine may provide relief for patients with Parkinson’s disease during periods of immobility related to ...
Learn everything you need to know about Apomorphine-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings ...
Apomorphine, a 150-year-old drug for Parkinson’s disease is found to lower ‘off’ time for people at an advanced stage of the disease. Apomorphine has been in use for many years, but its significance ...
Results from the first randomized, controlled trial investigating the efficacy and safety of APO-go ® /MOVAPO ® (apomorphine) subcutaneous infusion in Parkinson's disease (PD) patients whose motor ...
The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced Parkinson's disease, Supernus Pharmaceuticals announced on Tuesday. The ...
The benefits of the dopamine agonist apomorphine in Parkinson's disease have finally been confirmed in a randomized controlled trial, although the drug has been used in the condition for many years.
Lal et al 1 showed in a placebo-controlled double-blind study on healthy volunteers that apomorphine injected subcutaneously (s.c) was able to induce erection. However, side effects limited its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results